Monthly Archives: February 2014

Accele Biopharma Announces Executive Management Team at Synereca Pharmaceutics (SPI)

Accele Venture Partners I LP invests $500,000 in SPI.

OKLAHOMA CITY, OK, February 26, 2014 — Accele Biopharma, Inc. (Accele), an accelerator of early-stage biotechnology companies, today announced that the Company has assumed the management of Synereca Pharmaceutics, Inc. (SPI) in conjunction with an investment of approximately $500,000 to advance SPI’s research programs to discover and develop novel antibiotic products to treat resistant gram-negative infections. The investment was made by Accele Venture Partners 1 LP, the investing arm of Accele Biopharma.

Clayton I. Duncan, Accele Biopharma’s Chairman and Chief Executive Officer, will serve as Chairman and Chief Executive Officer of Synereca. Mr. Duncan has over 20 years’ experience as a biopharmaceutical CEO, heading six companies – Vindica Therapeutics, Ercole Biotech, Entegrion, Incara Pharmaceuticals Corporation, Sphinx Pharmaceuticals Corporation and CRX Medical.

“According to the CDC and WHO, antibiotic resistance is an imminent public health crisis,” said Mr. Duncan. “We are excited about Synereca’s novel programs to help restore the effectiveness of antibiotics in fighting resistant gram-negative infections.”

Additional members of SPI’s executive management team include:

  • Scott Singleton, PhD, Associate Professor of Pharmacy and Division Vice Chair at the UNC Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, will serve as SPI’s Chief Scientific Officer. Dr. Singleton’s laboratory at UNC focuses on the chemical biology of DNA metabolism as it relates to antibiotic resistance in bacterial pathogens.
  • Richard E. Gammans, PhD, will serve as SPI’s President and Chief Operating Officer. Dr. Gammans has more than 30 years’ experience in all aspects of drug R&D and scientific support of marketed products and has contributed to the development and regulatory approval of seven new molecular entities with over 50 national marketing authorizations in Western Europe and North America.
  • Kelle Jones, CPA, is SPI’s Chief Financial Officer. Ms. Jones has over 17 years of experience as an accountant or controller in a variety of business settings and previously spent nine years as senior accountant and then as site controller for Genzyme’s Oklahoma glycobiology research facility.
  • W. Bennett Love is SPI’s VP Business Operations. Mr. Love has held financial, strategic and general senior management positions in biotech companies since 1990.
  • Steven Bocckino PhD is SPI’s VP Pre-clinical Research. Dr. Bocckino has 20 years experience in the pharmaceutical industry and has held a variety of positions in drug discovery and development.

Synereca will maintain its current research facilities in Chapel Hill, NC. The Company’s corporate headquarters and additional research laboratories will relocate to the Accele Biopharma Inc. biotechnology accelerator facilities in Oklahoma City, OK.

About Synereca Pharmaceutics, Inc. (SPI)
SPI focuses on the discovery and development of compounds that increase or restore the effectiveness of existing antibiotics for infections caused by Gram-negative bacteria. SPI’s lead program focuses on inhibiting RecA-dependent SOS, the pathway primarily responsible for the bacteria’s abilities to escape antibiotic killing and to evolve resistance. Reducing or eliminating RecA activity in pathogenic bacteria allows the antibiotic to remain effective. SPI is also examining compounds that restore the effect of Colistin (polymyxin E) in bacterial strains that have become resistant to other frontline antibiotics. See www.synereca.com for additional information about SPI.

About Accele Biopharma, Inc.
Accele Biopharma (“Accele”) and Accele Venture Partners 1 LP, a related special purpose venture fund, were formed to create a capital-efficient mechanism to identify, finance and manage groundbreaking, early-stage life science technologies that have the potential to dramatically improve human healthcare, have strong commercial promise and have the potential for generating early proof of concept data. To achieve this goal Accele has assembled an experienced management team, a group of sophisticated investors, a nationally recognized advisory board, leading research facilities and the broad scientific expertise necessary to evaluate and manage such opportunities.

Founded in 2011, Accele is located on the Oklahoma Health Sciences University Campus in Oklahoma City. For more information on Accele Biopharma, please visit www.accelebio.com.

Cytovance Biologics, Inc. and Pamlico Biopharma Announce Development and cGMP Manufacturing Agreement

Oklahoma City, OK (February 18, 2014)– Cytovance Biologics, a leading full-service contract manufacturer (“CMO”) of mammalian and microbial biologics, announces that they have entered into a development and manufacturing agreement with Pamlico BioPharma, Inc., an Oklahoma City-based clinical stage biopharmaceutical company.

Pamlico BioPharma has developed a group of three human IgG monoclonal antibodies intended for the treatment of Streptococcus pneumoniae infections. Pamlico has contracted Cytovance Biologics as its CMO to develop a production cell line from the protein’s amino acid sequence for GMP manufacture of phase I clinical material.

“With this agreement, Pamlico BioPharma has reached a milestone in the development of a therapeutic antibody product for the treatment of Streptoccocus pneumoniae, a leading cause of Severe Community Acquired Pneumonia (SCAP) which can lead to hospitalization and death,” said Clayton Duncan, CEO of Pamlico BioPharma, Inc.

“Cytovance’s state-of-the-art facilities and experienced staff are prepared to deliver the highest quality of development and manufacturing services for Pamlico BioPharma,” said Darren Head, President and Chief Executive Officer of Cytovance Biologics. “We are delighted to be working with such an innovative company that uses technologies from the Oklahoma Medical Research Foundation and advance the treatment of Streptococcus pneumonia infections that are associated with over 50,000 deaths annually.”

About Pamlico BioPharma, Inc.
Pamlico Biopharma, Inc., an Accele Biopharma Inc. client company, was founded around human monoclonal antibody therapeutics and technologies from the Oklahoma Medical Research Foundation and from Emory University. PAMLICO focuses on human monoclonal antibody therapeutics for human pathogens, cancer and autoimmune diseases. The lead project will address SCAP caused by S pneumoniae. Pneumococcal pneumonia remains a major cause of morbidity and mortality worldwide.

About Accele Biopharma Inc.
Accele Biopharma (“Accele”) and Accele Venture Partners, a related special purpose venture fund, were formed to create a capital-efficient mechanism to identify, finance and manage groundbreaking, early-stage life science technologies that have the potential to dramatically improve human healthcare, have strong commercial promise and have the potential for generating early proof of concept data. To achieve this goal Accele has assembled an experienced management team, a group of sophisticated investors, a nationally recognized advisory board, research facilities and the broad scientific expertise necessary to evaluate and manage such opportunities.

Accele currently has four companies under management: Otologic Pharmaceutics, Inc. focusing on a clinical stage treatment for hearing loss; Pamlico Biopharma, Inc., focusing on human monoclonal antibody therapeutics for human pathogens, cancer and autoimmune diseases, with a lead project addressing pneumonia caused by S pneumoniae; Synereca Pharmaceuticals, Inc., developing novel drugs that inhibit the bacterial enzyme RecA to address the growing problem of antibiotic resistance; and Jortan Pharmaceuticals, Inc., pursuing the discovery and development of BACE-2 (Memapsin 1) inhibitors as a novel approach to the treatment of type 2 diabetes.
For further information regarding Accele Biopharma Inc. and Pamlico Biopharma, Inc., see http://www.accelebio.com

About Cytovance Biologics
Cytovance Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.

Learn more about Cytovance Biologics at www.cytovance.com.

Media Contact
Jodie Gutkowski
Marketing/Communications Manager
jgutkowski@cytovance.com

Richard Gammans PhD
President and COO
Pamlico Biopharma Inc
rgammans@accelebio.com